KARD (Kardigan, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KARD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | A | — | — |
| 2026-06-24 | PAUL L BERNS | Director | Buy | — | — |
| 2026-06-24 | ARCH Venture Partners XIII, LLC | Director | Buy | — | — |
| 2026-06-24 | Kevin Anthony Kelly | 10%+ Owner | Buy | — | — |
| 2026-06-22 | Douglas E. Giordano | Director | A | — | — |
| 2026-06-22 | Kimberly J Popovits | Director | A | — | — |
| 2026-06-22 | David P Meeker | Director | A | — | — |
| 2026-06-22 | Brianne Jahn | Chief Financial Officer | A | — | — |
| 2026-06-22 | John B Moriarty | Chief Legal Officer | A | — | — |
| 2026-06-22 | Timothy P Walbert | Director | A | — | — |
| 2026-06-22 | Jay Edelberg | Chief Medical Officer | MIXED | — | — |
| 2026-06-22 | PAUL L BERNS | Director | MIXED | — | — |
| 2026-06-22 | Andy Pasternak | Chief Strategy Officer | A | — | — |
| 2026-06-22 | ANASTASIOS GIANAKAKOS | President & CEO | C | — | — |
| 2026-06-22 | ARCH Venture Fund XIII, L.P. | 10%+ Owner | C | — | — |
| 2026-06-22 | SCHF CIF 2024, L.P. | 10%+ Owner | C | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 15,062,741 | — |
| — | Director | 15,042,035 | — |
| — | 10%+ Owner | 13,792,035 | — |
| — | 10%+ Owner | 6,150,502 | — |
| — | Chief Medical Officer | 4,595,383 | — |
| — | 10%+ Owner | 2,050,166 | — |
| — | President & CEO | 548,513 | — |
| — | Chief Strategy Officer | 79,640 | — |
| — | Chief Financial Officer | 79,640 | — |
| — | Chief Legal Officer | 47,784 | — |
| — | Director | 20,706 | — |
| — | Director | 20,706 | — |
| — | Director | 20,706 | — |
| — | Director | 20,706 | — |
| — | Director | 20,706 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KARD quote page; the site-wide leaderboard is on the insider transactions hub.